secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001140361-23-014660
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics reports 2022 net loss of $38.9M; NAVIGATE trial on track
------------------------------------------------------------------------------

- Net loss $38.9M ($0.65/share) vs $30.7M ($0.52) in 2021.
- R&D expenses $31.7M, up from $23.8M, driven by NAVIGATE trial costs.
- Cash $18.6M; $50M credit line available; expects funding through Dec 2024.
- NAVIGATE trial randomized 357 patients; DSMB positive; interim results Q4 2024.
- Evaluating Phase 2 trial of belapectin + Keytruda for head and neck cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123014660/0001140361-23-014660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036123014660/brhc10050428_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-014660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer